non steroid anti inflammatory and COX-2 selective (COXIB) have been associated with a higher cardiovascular
risk. The risk of possible negative results related to the treatment of patients that take COXIB, through the search in data bases of
patients affiliated to the generalized health system is to be determined.
through the use of a medicine data base of 3.7 million affiliates, using a Business Objective tool on an Oracle platform,
statistics were obtained from January 1, 2007 through May 31 2011, differentiated by age, gender, city, insurance company,
medication, time length of consumption and co-medication applied.
a sample of 176 patients was found, mainly women (66.0%) with an age mean of 59.8 years in 22 cities throughout the
country. The prescribed medications were Celecoxib (79.5%) and Etoricoxib (20.5%). The average time length of use of COXIB
was 8.1 months (range: 1 ? 48 months). 81 patients with some risk of cardiovascular problems and hypertension were found
(n=70; 22;5%), dyslipidemia (n=22; 7.1%), diabetes mellitus (n=12; 3.9%) and 7 patients with the use of COXIB for more than
18 months and cardiovascular risk associated, which were reported to the person in charge of sanitary services, who notified the
modification of the therapy.
Drug surveillance allows the optimization of resources and the prevention of negative results associated with the
prescription of drugs that may cause incidences of diseases or death. The search in data bases to reinforce the vigilant programs
of the use of medications in the country, in order to improve the quality of the prescription, is recommended.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals